Patents by Inventor Mark D. Cochran

Mark D. Cochran has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RECOMBINANT VIRUS EXPRESSING FOREIGN DNA ENCODING FELINE CD80, FELINE CD86, FELINE CD28, OR FELINE CTLA-4 AND USES THEREOF
    Publication number: 20080145382
    Abstract: The present invention involves a recombinant virus which comprises at least one foreign nucleic acid inserted within a non-essential region of the viral genome of a virus, wherein each such foreign nucleic acid encodes a protein. The protein which is encoded is selected from the groups consisting of a feline CD28 protein or an immunogenic portion thereof, a feline cD80 protein or an immunogenic portion thereof, a feline CD86 protein or an immunogenic portion thereof, or a feline CTLA-4 protein or an immunogenic portion thereof. The protein is capable of being expressed when the recombinant virus is introduced into an appropriate host. The present invention also involves a recombinant virus further comprising a foreign nucleic acid encoding an immunogen derived from a pathogen. The present invention also comprises recombinant viruses which are capable of enhancing an immune response in a feline.
    Type: Application
    Filed: August 17, 2007
    Publication date: June 19, 2008
    Inventors: Ellen W. Collisson, Stephen M. Hash, Insoo Choi, Barbara J. Winslow, Mark D. Cochran
  • Neutralizing GDF8 epitope-based growth enhancing vaccine
    Patent number: 7371726
    Abstract: The invention provides new, specific antigenic peptides from the protein GDF8. The invention also provides fusion proteins comprising the new peptides, immunogens and vaccines based on the new peptides and/or fusion proteins, antibodies that specifically bind to the new peptides of GDF8, and methods of treating animals in order to modulate the activity of GDF8, employing vaccines or antibodies according to the invention.
    Type: Grant
    Filed: December 21, 2004
    Date of Patent: May 13, 2008
    Assignee: Schering-Plough Animal Health Corporation
    Inventors: David E. Junker, Mark D. Cochran
  • Recombinant infectious laryngotracheitis virus and uses thereof
    Patent number: 7364893
    Abstract: The present invention provides recombinant and/or isolated infectious laryngotracheitis virus glycoproteins, including gD, gI, gG and gE.
    Type: Grant
    Filed: January 27, 2006
    Date of Patent: April 29, 2008
    Assignee: Schering-Plough Animal Health Corp.
    Inventors: Martha A. Wild, Mark D. Cochran
  • Recombinant avian herpesvirus useful in vaccine production
    Patent number: 7314715
    Abstract: The present invention provides a novel avian herpesvirus (NAHV) vector and recombinant vaccines made therefrom that are useful to immunize avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease. Methods of immunizing an avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease are also provided.
    Type: Grant
    Filed: May 11, 2005
    Date of Patent: January 1, 2008
    Assignee: Schering-Plough Animal Health Corporation
    Inventors: Mark D. Cochran, Stephanie M. Cook, Martha A. Wild
  • Recombinant virus expressing foreign DNA encoding feline CD86 and uses thereof
    Patent number: 7279168
    Abstract: The present invention involves a recombinant virus which comprises at least one foreign nucleic acid inserted within a non-essential region of the viral genome of a virus, wherein each such foreign nucleic acid encodes a protein. The protein which is encoded is selected from the groups consisting of a feline CD28 protein or an immunogenic portion thereof, a feline cD80 protein or an immunogenic portion thereof, a feline CD86 protein or an immunogenic portion thereof, or a feline CTLA-4 protein or an immunogenic portion thereof. The protein is capable of being expressed when the recombinant virus is introduced into an appropiate host. The present invention also involves a recombinant virus further comprising a foreign nucleic acid encoding an immunogen derived from a pathogen. The present invention also comprises recombinant viruses which are capable of enhancing an immune response in a feline.
    Type: Grant
    Filed: April 30, 1999
    Date of Patent: October 9, 2007
    Assignees: Texas A & M University System, Schering-Plough Animal Health Corporation
    Inventors: Barbara J. Winslow, Mark D. Cochran, Stephen Hash, Insoo Choi, Ellen Collisson
  • Nucleic acid encoding feline CD86
    Patent number: 7078512
    Abstract: The present invention provides isolated and purified DNA encoding feline CD80 (B7-1) ligand, feline CD86 (B7-2) ligand, feline CD28 receptor, or feline CTLA-4 (CD152) receptor, as well as vectors comprising nucleic acid encoding feline CD80, feline CD86, feline CD28, or feline CTLA-4. The present invention provides a host cells transformed with CD80-encoding vectors, CD86-encoding vectors, CD28-encoding vectors, or CTLA-4-encoding vectors. The invention provides polypeptides encoded by the nucleic acid of feline CD80, feline CD86, feline CD28, or feline CTLA-4.
    Type: Grant
    Filed: April 30, 1999
    Date of Patent: July 18, 2006
    Assignees: Schering-Plough Animal Health Corporation, The Texas A & M University System
    Inventors: Ellen W. Collisson, InSoo Choi, Barbara J. Winslow, Mark D. Cochran
  • Recombinant infectious laryngotracheitis virus and uses thereof
    Patent number: 7045598
    Abstract: The present invention provides recombinant and/or isolated infectious laryngotracheitis virus glycoproteins, including gD, gl, gG and gE.
    Type: Grant
    Filed: April 30, 2004
    Date of Patent: May 16, 2006
    Assignee: Schering-Plough Animal Health
    Inventors: Martha A. Wild, Mark D. Cochran
  • Recombinant infectious laryngotracheitis virus and uses thereof
    Patent number: 6984728
    Abstract: Recombinant, attenuated infectious laryngotracheitis virus containing a deletion or deletion in a glycoprotein gene are provided. Also provided are glycoprotein genes, gD, gI, gG, and gE as well as other viral genes.
    Type: Grant
    Filed: November 6, 2001
    Date of Patent: January 10, 2006
    Assignee: Schering Corporation
    Inventors: Martha A. Wild, Mark D. Cochran
  • Recombinant avian herpesvirus useful in vaccine production
    Patent number: 6913751
    Abstract: The present invention provides a novel avian herpesvirus (NAHV) vector and recombinant vaccines made therefrom that are useful to immunize avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease. Methods of immunizing an avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease are also provided.
    Type: Grant
    Filed: June 14, 2001
    Date of Patent: July 5, 2005
    Assignee: Schering-Plough Veterinary Corporation
    Inventors: Mark D. Cochran, Stephanie M. Cook, Martha A. Wild
  • Recombinant infectious laryngotracheitis virus and uses thereof
    Patent number: 6875856
    Abstract: Recombinant, attenuated infectious laryngotracheitis viruses containing a deletion or deletions in a glycoprotein gene are provided. Also provided are glycoprotein genes, gD, gI, gG and gE as well as other viral genes.
    Type: Grant
    Filed: November 6, 2001
    Date of Patent: April 5, 2005
    Assignee: Syntro Corporation
    Inventors: Martha A. Wild, Mark D. Cochran
  • Novel recombinant and mutant adenoviruses
    Publication number: 20040234549
    Abstract: The present invention provides novel viral vectors. In one embodiment, the present invention provides mutant and recombinant bovine adenoviruses having a deletion and/or insertion of DNA in the early gene region 4 (E4). In another embodiment, the present invention provides mutant and recombinant bovine adenovirus 1 viruses having a deletion and/or insertion of DNA in the early gene region 3 (E3). The present invention also contemplates the use of the viral vectors for vaccination, gene therapy or other applications as suitable.
    Type: Application
    Filed: June 23, 2004
    Publication date: November 25, 2004
    Inventors: Christina H. Chiang, Mark D. Cochran
  • Recombinant infectious laryngotracheitis virus and uses thereof
    Publication number: 20040228878
    Abstract: The present invention provides recombinant and/or isolated infectious laryngotracheitis virus glycoproteins, including gD, gl, gG and gE.
    Type: Application
    Filed: April 30, 2004
    Publication date: November 18, 2004
    Inventors: Martha A. Wild, Mark D. Cochran
  • RECOMBINANT INFECTIOUS LARYNGOTRACHEITIS VIRUS AND USES THEREOF
    Publication number: 20040171132
    Abstract: The present invention provides a recombinant, attenuated infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the glycoprotein gG gene. This attenuated virus is useful as a vaccine against infectious laryngotracheitis virus.
    Type: Application
    Filed: November 6, 2001
    Publication date: September 2, 2004
    Inventors: Martha A. Wild, Mark D. Cochran
  • Novel recombinant and mutant adenoviruses
    Publication number: 20030108569
    Abstract: The present invention provides novel viral vectors. In one embodiment, the present invention provides mutant and recombinant bovine adenoviruses having a deletion and/or insertion of DNA in the early gene region 4 (E4). In another embodiment, the present invention provides mutant and recombinant bovine adenovirus 1 viruses having a deletion and/or insertion of DNA in the early gene region 3 (E3). The present invention also contemplates the use of the viral vectors for vaccination, gene therapy or other applications as suitable.
    Type: Application
    Filed: July 19, 2002
    Publication date: June 12, 2003
    Inventors: Christina H. Chiang, Mark D. Cochran
  • Recombinant infectious laryngotracheitis virus and uses thereof
    Publication number: 20030082788
    Abstract: The present invention provides a recombinant, attenuated infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the glycoprotein gG gene. This attenuated virus is useful as a vaccine against infectious laryngotracheitis virus.
    Type: Application
    Filed: November 6, 2001
    Publication date: May 1, 2003
    Inventors: Martha A. Wild, Mark D. Cochran
  • Recombinant swinepox virus
    Patent number: 6497882
    Abstract: This invention provides a recombinant swinepox virus comprising a foreign DNA sequence inserted into the swinepox virus genomic DNA, wherein the foreign DNA sequence is inserted within a HindIII K fragment of the swinepox virus genomic DNA and is capable of being expressed in a swinepox virus infected host cell. The invention further provides homology vectors, vaccines and methods of immunization.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 24, 2002
    Assignee: Syntro Corporation
    Inventors: Mark D. Cochran, David E. Junker
  • Recombinant and mutant adenoviruses
    Patent number: 6451319
    Abstract: The present invention provides novel viral vectors. In one embodiment, the present invention provides mutant and recombinant bovine adenoviruses having a deletion and/or insertion of DNA in the early gene region 4 (E4). In another embodiment, the present invention provides mutant and recombinant bovine adenovirus 1 viruses having a deletion and/or insertion of DNA in the early gene region 3 (E3). The present invention also contemplates the use of the viral vectors for vaccination, gene therapy or other applications as suitable.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: September 17, 2002
    Assignee: Schering-Plough Veterinary Corporation
    Inventors: Christina H. Chiang, Mark D. Cochran
  • Novel avian herpes virus and uses thereof
    Publication number: 20020081316
    Abstract: The present invention provides a novel avian herpesvirus (NAHV) vector and recombinant vaccines made therefrom that are useful to immunize avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease. Methods of immunizing an avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease are also provided.
    Type: Application
    Filed: June 14, 2001
    Publication date: June 27, 2002
    Inventors: Mark D. Cochran, Stephanie M. Cook, Martha A. Wild
  • Recombinant feline herpesvirus comprising a foreign DNA inserted into a region corresponding to a 3.0 kb EcoRI-SalI fragment of a feline herpesvirus genome
    Patent number: 6410311
    Abstract: This invention provides a recombinant feline herpesvirus comprising a foreign DNA inserted into a feline herpesvirus genome, wherein the foreign DNA is inserted into a region of the genome which corresponds to the 3.0 kb EcoRI-SalI fragment within a SalI A fragment of the feline herpesvirus genome and is capable of being expressed in a host cell into which the virus is introduced. Further this invention provides a recombinant feline herpesvirus comprising a feline herpesvirus genome, wherein the feline herpesvirus genome contains a deletion in a SacII site within the 3.0 kb EcoRI-SalI fragment of the SalI A fragment of the feline herpesvirus genome. Lastly, this invention provides vaccines and methods of immunization of animals infected with feline herpesvirus.
    Type: Grant
    Filed: May 9, 1997
    Date of Patent: June 25, 2002
    Assignee: Schering-Plough Veterinary Corporation
    Inventors: Mark D. Cochran, Barbara J. Winslow
  • Recombinant infectious bovine rhinotracheitis virus
    Patent number: 6410033
    Abstract: The present invention provides a recombinant infectious bovine rhinotracheitis designated S-IBR-052 (ATCC Accession No. VR 2443). The present invention also provides a vaccine which comprises an effective immunizing amount of the recombinant infectious bovine rhinotracheitis virus designated S-IBR-052 and a suitable carrier. The present invention provides homology vectors, methods of immunization and a method of distinguishing an animal vaccinated with the vaccines of the present invention from an animal infected with a naturally-occurring infectious bovine rhinotracheitis virus.
    Type: Grant
    Filed: August 5, 1996
    Date of Patent: June 25, 2002
    Assignee: Syntro Corporation
    Inventor: Mark D. Cochran